Drugs / prifetrastat
last change May 2026 re-read 2 minutes ago

prifetrastat

also known as PF-07248144

Small molecule targets KAT6A, KAT6B via inhibition

Developed for
breast cancer · castration-resistant prostate carcinoma · metastatic melanoma · non-small cell lung carcinoma
Investigated by
Pfizer · UNICANCER

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07335419 Jan → Feb 2026 overdue Pfizer Active not recruiting No outcome recorded
Phase 1 NCT07423286 Oct → Dec 2025 Pfizer Completed No outcome recorded
Phase 1 NCT07198035 Sep → Dec 2025 Pfizer Completed No outcome recorded
Phase 1 NCT07636018 Aug → Oct 2025 Pfizer Completed No outcome recorded
Phase 1 NCT07117799 Feb → Jun 2025 Pfizer Completed No outcome recorded
Phase 22 trials
Phase 2 NCT07340619 May 2026 → Nov 2028 expected metastatic melanoma UNICANCER Not yet recruiting No outcome recorded
Phase 2 NCT04606446 Nov 2020 → Jul 2029 expected breast cancer, castration-resistant prostate carcinoma, non-small cell lung carcinoma Pfizer Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07062965 Aug 2025 → Jul 2027 expected breast cancer Pfizer Recruiting No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as prifetrastat ClinicalTrials.gov intervention name — accepted as the source's own label NCT07340619
Known as PF-07248144 “A new drug, prifetrastat (PF-07248144), which targets KAT6 proteins, which play a role in the growth of cancer cells, has shown promising results.” NCT07340619
7

NCT07335419

NCT07636018

NCT07117799

NCT07062965

NCT04606446

NCT07198035

NCT07423286

Action Inhibit “PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.” PMID 38824244 Jun 2024
Modality Small molecule CHEMBL6068620
Route Oral “taken by mouth” NCT07062965
Target KAT6A “PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.” PMID 38824244 Jun 2024
Target KAT6B “PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.” PMID 38824244 Jun 2024